Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain Age

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,762 result(s) found for: Brain Age. Displaying page 1 of 89.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-003342-29 Sponsor Protocol Number: fotgm Start Date*: 2007-10-31
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Second line therapy with low dose fotemustine in progressive malignant gliomas
    Medical condition: Progressive malignant gliomas patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006131 Brain neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013128-22 Sponsor Protocol Number: HE 42/09 Start Date*: 2010-06-29
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from lung and breast tumors. A phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
    Medical condition: Patients with brain metastases from lung and breast tumors
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003716-12 Sponsor Protocol Number: RHNIA-001-2021 Start Date*: 2022-08-24
    Sponsor Name:Rigshospitalet
    Full Title: S-ketamine for cortical spreading depolarisation in patients with severe acute brain injury
    Medical condition: Severe acute brain injury caused by aneurysmal subarachnoid hemorrhage, spontaneous intracerebral hemorrhage or traumatic brain injury.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10018061 General anesthesia LLT
    21.1 100000004865 10070731 Electrocorticography LLT
    20.0 100000004852 10056389 Brain damage LLT
    21.0 100000004852 10019529 Hemorrhage brain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012338-56 Sponsor Protocol Number: VAS203/II/1/03 Start Date*: 2009-07-10
    Sponsor Name:vasopharm GmbH
    Full Title: AN EXPLORATIVE PHASE IIa STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF VAS203 IN PATIENTS WITH MODERATE AND SEVERE TRAUMATIC BRAIN INJURY
    Medical condition: Moderate and severe traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060690 Traumatic brain injury LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000088-92 Sponsor Protocol Number: F7CBI-1600 Start Date*: 2004-08-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/Niastase®) with Brain Cont...
    Medical condition: Contusive Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052346 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003618-18 Sponsor Protocol Number: M10-897 Start Date*: 2013-04-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Su...
    Medical condition: Brain metastases from NSCLC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BE (Completed) CZ (Completed) FI (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-005669-54 Sponsor Protocol Number: UKM2013_0034 Start Date*: 2020-06-02
    Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with supratentorial brain tumours
    Medical condition: supratentorial intra-axial brain tumor (malignant glioma, astrocytoma, malignant ependymoma, AT/RT, Oligodendroglioma, etc.)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006154 Brain tumor NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005693-31 Sponsor Protocol Number: 312021 Start Date*: 2008-03-04
    Sponsor Name:BAYER
    Full Title: Contrast-enhanced MRI examination of cerebral neoplastic enhancing lesions: comparison of diagnostic efficacy of Gd-DOTA 0.5 M and gadobutrol 1.0 M at 0.1 mmol Gd/kg body weight: Intra-individual ...
    Medical condition: patients with cerebral neoplastic lesions
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006131 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004244-37 Sponsor Protocol Number: 13HH1824 Start Date*: 2014-02-21
    Sponsor Name:Imperial College London | Imperial College NHS Healthcare Trust
    Full Title: The control of brain networks after traumatic brain injury: a neuroimaging and neuropsychological study of dopamine and cognition
    Medical condition: Traumatic Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004863 10060690 Traumatic brain injury LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002813-11 Sponsor Protocol Number: ISRCTN23625128 Start Date*: 2007-01-02
    Sponsor Name:Xytis Pharmaceuticals Sàrl
    Full Title: A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury
    Medical condition: Moderate to Severe Traumatic Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060690 Traumatic brain injury LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Completed) BE (Completed) EE (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002109-58 Sponsor Protocol Number: RSR13 RT-016 Start Date*: 2005-02-14
    Sponsor Name:ALLOS Therapeutics, Inc.
    Full Title: A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 (efaproxiral), in Women with Brain Metastases...
    Medical condition: Brain metastases from breast cancer
    Disease: Version SOC Term Classification Code Term Level
    4.0 10027453 4
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) HU (Completed) GB (Completed) LT (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003227-35 Sponsor Protocol Number: 755/11 Start Date*: 2011-10-04
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: 18F-FECh-PET in patients with brain tumors
    Medical condition: brain tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061030 Brain tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005194-32 Sponsor Protocol Number: CRANIAL Start Date*: 2013-06-28
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer
    Medical condition: Brain metastasis secondary to HER2-negative breast cancer and NSCLC, not previously irradiated and not requiring immediate radiation.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059282 Metastases to central nervous system PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000661-12 Sponsor Protocol Number: OCTO_022 Start Date*: 2011-08-23
    Sponsor Name:University of Oxford
    Full Title: A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases
    Medical condition: Metastatic melanoma with brain metastases.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006694-39 Sponsor Protocol Number: ASF-CP02-001 Start Date*: 2022-07-08
    Sponsor Name:Lantmännen Medical AB
    Full Title: An open-label, historical cohort control study to evaluate the safety and tolerability of AF-16 in patients with cerebral oedema caused by traumatic brain injury (TBI)
    Medical condition: Cerebral oedema caused by traumatic brain injury (TBI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    20.1 100000004852 10008127 Cerebral oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001409-40 Sponsor Protocol Number: S334.2.002 Start Date*: 2009-03-04
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: A Randomized, Double blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients with ...
    Medical condition: Moderate and severe Traumatic Brain Injury (TBI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060690 Traumatic brain injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004512-58 Sponsor Protocol Number: INV-GEM-0200-I Start Date*: 2020-08-17
    Sponsor Name:Technische Universität München, Fakultät für Medizin
    Full Title: Comparison of Fluorescein-INtra-VItal microscopy Versus conventional frozen section diagnosis for intraOperative histopathological evaluation
    Medical condition: Intracranial tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006153 Brain tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002433-15 Sponsor Protocol Number: RS200511 Start Date*: 2021-02-15
    Sponsor Name:Region Skåne
    Full Title: Positron emission tomography (PET) of patients with brain injury and athletes with concussion symptoms - Descriptive study of the tau tracer 18F-RO6958948
    Medical condition: Traumatic brain injury (TBI), cerebral haemorrhage (ICH), subarachnoid haemorrhage (SAH) and cerebral commotio.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10070976 Craniocerebral injury PT
    20.1 100000004852 10042320 Subarachnoid hemorrhage LLT
    20.1 10022117 - Injury, poisoning and procedural complications 10060690 Traumatic brain injury LLT
    21.1 100000004852 10022754 Intracerebral hemorrhage LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005647-24 Sponsor Protocol Number: MIA2019/CT/258 Start Date*: 2021-05-10
    Sponsor Name:Melanoma Institute Australia
    Full Title: A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain met...
    Medical condition: melanoma brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005247-10 Sponsor Protocol Number: ITCC-003-Tarceva/Roche MO 18461 Start Date*: 2005-07-29
    Sponsor Name:The University Hospitals of Leicester NHS Trust
    Full Title: Phase I study of TARCEVA (Erlotinib Hydrochloride, OSI-774) as a single agent in children with refractory and relapsed malignant brain tumours and in combination with irradiation in newly diagnosed...
    Medical condition: Refractory and relapsed malignant brain tumours and newly diagnosed brain stem glioma.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA